Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Sep;20(3):2722.
doi: 10.18549/PharmPract.2022.3.2722. Epub 2022 Sep 14.

Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study

Affiliations

Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study

Asim Ahmed Elnour et al. Pharm Pract (Granada). 2022 Jul-Sep.

Abstract

Background: Warfarin is well known as a narrow therapeutic index that has prodigious variability in response which challenges dosing adjustment for the maintenance of therapeutic international normalized ratio. However, an appreciated population not on new oral anticoagulants may still need to be stabilized with warfarin dosing.

Objective: The current study's main objective was to validate and compare two models of warfarin clinical algorithm models namely the Gage and the International Warfarin Pharmacogenetics Consortium (IWPC) with warfarin 5 mg fixed standard dosing strategy in a sample of Sudanese subjects.

Method: We have conducted a cross-sectional study recruited from the out-patient clinic at a tertiary specialized heart center. We included subjects with unchanged warfarin dose (stabilized), and with therapeutic international normalized ratio. The predicted doses of warfarin in the two models were calculated by three different methods (accuracy, clinical practicality, and the clinical safety of the clinical algorithms).

Main outcome measure: The primary outcomes were the measurements of the clinical (accuracy, practicality, and safety) in each of the two clinical algorithms models compared to warfarin 5 mg fixed standard dose strategy.

Results: We have enrolled 71 Sudanese subjects with mean age (51.7 ± 14 years), of which (49, 69.0%) were females. There was no significant difference between the warfarin 5 mg fixed standard dose strategy and the predicted doses of the two clinical algorithm models (MAE 1.44, 1.45, and 1.49 mg/day [P =0.4]) respectively. In the clinical practicality, all of the three models had a high percent of subjects (95.0%, 51.9%, and 66.7%) in the ideal dose range in middle dose group (3-7 mg/ day) for warfarin 5 mg fixed standard dosing strategy, Gage, and IWPC clinical algorithm models respectively. However, a small percent of subjects was exhibited in the warfarin low dose group ≤ 3 mg/day (0.0%, 15.0%, and 10.0%) and warfarin high dose group ≥ 7 mg/day (0.0%, 33.3%, and 33.3%) for warfarin 5 mg fixed standard dosing strategy, Gage, and IWPC clinical algorithms respectively. In terms of clinical safety, the percent of subjects with severely over-prediction were 28.2%, 22.5%, and 22.5% for warfarin 5 mg fixed standard dosing, Gage, and IWPC, respectively. While the percent of severely under-prediction was 12.7%, 7.0%, and 5.6% for the warfarin 5 mg fixed standard dosing, Gage, and IWPC, respectively.

Conclusion: The Gage and IWPC clinical algorithm models were accurate, more clinically practical, and clinically safe than warfarin 5 mg standard dosing in the study population. The cardiologist can use either models (Gage and IWPC) to stratify subjects for accurate, practical, and clinically safe warfarin dosing..

Keywords: accuracy; clinical safety; over-prediction; practicality; under-prediction; warfarin clinical algorithms; warfarin fixed standard dosing strategy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The prediction of clinical practicality in the two clinical algorithms models (Gage and IWPC) compared to warfarin 5 mg fixed standard dosing strategy Keys: Gage: Gage clinical algorithm; IWPC: international warfarin pharmacogenetic consortium clinical algorithm; in the low dose and high dose groups, both Gage and IWPC had high prediction.
Figure 2
Figure 2
The clinical safety of the two clinical algorithms models (Gage and IWPC) compared to warfarin 5 mg fixed standard dosing strategy Keys: Gage: Gage clinical algorithm; IWPC: international warfarin pharmacogenetic consortium clinical algorithm. The Gage and IWPC clinical algorithms had less severely under prediction compared to warfarin 5 mg fixed standard dosing.
Figure 3
Figure 3
The clinical safety in their different dose ranges comparing the two clinical algorithms models (Gage and IWPC) to warfarin 5 mg fixed standard dosing strategy Keys: Gage: Gage clinical algorithm; IWPC: international warfarin pharmacogenetic consortium clinical algorithm. The Gage and IWPC had better performance in severely under-prediction and severely over-prediction.

References

    1. 1. Roper N, Storer B, Bona R, et al. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. J Mol Diagn. 2010;12(3):283-291. https://doi.org/10.2353/jmoldx.2010.090110 - PMC - PubMed
    2. Roper N, Storer B, Bona R, et al. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. J Mol Diagn. 2010;12(3):283–291. doi: 10.2353/jmoldx.2010.090110. - DOI - PMC - PubMed
    1. 2. Finkelman BS, Gage BF, Johnson JA, et al. Genetic Warfarin Dosing:Tables Versus Algorithms. J Am Coll Cardiol. 2011;57(5):612-618. https://doi.org/10.1016/j.jacc.2010.08.643 - PMC - PubMed
    2. Finkelman BS, Gage BF, Johnson JA, et al. Genetic Warfarin Dosing:Tables Versus Algorithms. J Am Coll Cardiol. 2011;57(5):612–618. doi: 10.1016/j.jacc.2010.08.643. - DOI - PMC - PubMed
    1. 3. Kimmel SE, French B, Kasner SE, et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med. 2013;369(24):2283-93. https://doi.org/10.1056/NEJMoa1310669 - PMC - PubMed
    2. Kimmel SE, French B, Kasner SE, et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med. 2013;369(24):2283–93. doi: 10.1056/NEJMoa1310669. - DOI - PMC - PubMed
    1. 4. Hamberg A-K, Hellman J, Dahlberg J, et al. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Med Inform Decis Mak. 2015;15:7. https://doi.org/10.1186/s12911-014-0128-0 - PMC - PubMed
    2. Hamberg A-K, Hellman J, Dahlberg J, et al. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Med Inform Decis Mak. 2015;15:7. doi: 10.1186/s12911-014-0128-0. - DOI - PMC - PubMed
    1. 5. Cho S, Lee K, Choi JR, et al. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei Med J. 2016;57(3):635-640. https://doi.org/10.1056/NEJMoa1310669 - PMC - PubMed
    2. Cho S, Lee K, Choi JR, et al. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei Med J. 2016;57(3):635–640. doi: 10.1056/NEJMoa1310669. - DOI - PMC - PubMed

LinkOut - more resources